

A Sustainable Future Powered by Electricity

## **EAI Viewpoints**

Senior Stakeholder Meeting

# **Industry High Level Concerns**

- 1. Quality assurance
- 2. Timeframe for delivery
- 3. Costs
- 4. Europe
- 5. Conclusion



# **Quality Assurance of Product**

- **EAI concerns**: Will final design lead to closer market integration and realise the welfare gains/benefits identified in HLD?
  - Project management basic processes: design, management and assurance
    - No definitive critical pathway with checkpoints
    - Market rules trailing system design
  - System readiness focus Do not see Commercial readiness on agenda
  - Market cannot be suspended after go-live (cannot unwind EUPHEMIA contracts)

### Examples

- Change control changes made without industry input/agreement
- Market design remains untested despite concerns raised by independent consultants
- Development of central market systems prior to finalisation of market rules
- DS3 HLD not implementable revised decision
- Lack of formal consultation on interim IDM solution (Governance) concerns regarding efficacy

- Independent QA of ISEM project (across all 3 workstreams)
- Reflection period to prepare updated implementation plan: key remaining elements; development programme for each; sequencing plan
- Definitive critical path with key checkpoints (defined go/no go decision points based on objective criteria)
- Robust governance including formalised roles for WGs and processes
- If element of market not functioning then need to modify/remove downstream obligations



# Timeframe for delivery

- EAI concerns: Building a market not just a system
  - XBID delivery and SEM-15-065 (p. 38):
    - The XBID project is expected to be operational in 2017. However, this places a risk for I-SEM as any delay to XBID would likely result in a delay to I-SEM Go Live
  - Over-optimistic expectation by RAs re participant system readiness timeframes
  - Time allocation for Test regime will address systems functioning only
    - What commercial outcome will code deliver under real market conditions?

### Examples

- Timelines for ETA rules development inadequate
  - Developing of ETA rules in absence of NEMO rules
- Development of CRM settlement rules being completed prior to key policy decisions
- Minimal timeline for development of Capacity Market Code

- Implement recommended Quality Assurance process, as per previous slide:
  - Commercial trials in addition to system trials on key areas of the market design
  - Trials should be developed in conjunction with industry, similar to EUPHEMIA Trialling process
  - Describe consequences where failures identified (Plan Bs)
- Must properly consider commercial robustness of arrangements and participant readiness
  - RAs and participants need to put in place risk management structures



## **Costs**

#### EAI concerns

- Cost of central systems redesign given current approach
- Participants now commencing own system development under same conditions
- Accountability for design has moved to TSOs market players have limited influence

### Examples

- Initial participant cost estimates in I-SEM Impact Assessment not credible
- Risk of substantial change control costs for central systems and market participants
- Complexity of market arrangements significantly increases systems implementation costs

- Currently tail wagging the dog: Take design decisions first, write rules, then develop software
- EUPHEMIA testing imperfect but invaluable: need similar approach for IDM, BM and dispatch and scheduling processes prior to market trials



# **Europe**

#### EAI concerns

- The future of electricity decarbonised, decentralised, digitised
  - Risk that current market arrangements do not support this
- Recognition at EU level that Target Model itself needs to change
  - Winter package: RES (50%+) integration to market
  - "radical change to market design needed" (Canete) and Brussels de facto recognition it is not fit for purpose
- XBID non-delivery: implications for pan-European CACM compliance can any Member State be fully compliant by end 2017?
- CRM State Aid approval not assured

- Developments in wider EU context require careful consideration
- Impact of delayed state aid approval of CRM contingency measures need consideration
- Determine legal implications of XBID non-delivery



## **Conclusions**

- Robust quality assurance required in line with best practice
- Need commercial testing regime
- Compressed timeframe is increasing risk of added delivery costs
  - Risk of increase costs for consumers and to security of supply
- Need to be mindful of ongoing changes to the wider European context

Risk of non-compliance needs to be carefully balanced against the long term costs to I-SEM consumers of flaws in market design

